1
Clinical Trials associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
The purpose of this study is to evaluate the vaccine efficacy (VE) of a heterologous vaccine regimen utilizing Ad26.Mos4.HIV and aluminum phosphate-adjuvanted Clade C gp140 and Mosaic gp140 for the prevention of HIV-1 infection in HIV-1 seronegative cis-gender men and transgender individuals having sex with cis-gender men and/or transgender individuals.
100 Clinical Results associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)
100 Translational Medicine associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)
100 Patents (Medical) associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)
100 Deals associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)